News Headlines

  1. Signant Health And Actigraph Simplify Clinical Trial Activity And Sleep Monitoring For Patients, Sites, And Sponsors With Their New Integration

    Signant Health, formerly CRF Health and Bracket, is proud to announce that it has integrated its industry leading eCOA platform TrialMax, with ActiGraph’s CentrePoint system.

  2. Premier Research Renews Sponsorship For World Orphan Drug Congress Europe

    Premier Research is proud to once again be a sponsor of the World Orphan Drug Congress (WODC) Europe taking place November 12-14, 2019, in Barcelona, Spain. As part of our ongoing support for this innovative conference, Jonathan Kornstein, Executive Director, Program Strategy, Rare Disease & Pediatrics, will present a session entitled "A Partnership That Lasts: Key Considerations When Working With CROs on Rare Disease Studies."

  3. Signant Health Proud To Sponsor The Philadelphia Walk To End Alzheimer’s In Nationwide Effort To Build Awareness, Raise Funds And Advance Research Towards A Cure

    Signant Health, formerly CRF Health and Bracket, announced today that it is sponsoring the Philadelphia Walk to End Alzheimer’s. The walk, which takes place on November 10, 2019 at Citizens Bank Park, Philadelphia, PA, is an annual fundraising event held by the Alzheimer’s Association.

  4. Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results From URIROX-1 Trial And From Study 206

    Allena Pharmaceuticals, Inc. a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced positive topline results from URIROX-1, its first Phase 3 pivotal trial evaluating reloxaliase in patients with enteric hyperoxaluria (EH), as well as additional data from Study 206, its Phase 2 trial evaluating reloxaliase in high-risk patients with EH and advanced chronic kidney disease (CKD).

  5. Penumbra Indigo Aspiration System IDE Trial For Acute Pulmonary Embolism Meets Primary Safety And Efficacy Endpoints

    Penumbra, Inc. a global healthcare company focused on innovative therapies, today announced that the EXTRACT-PE trial successfully met the primary endpoints, demonstrating the safety and efficacy of the Indigo Aspiration System for aspiration mechanical thrombectomy in patients with acute pulmonary embolism (PE).

  6. Kayentis Opens Japanese Subsidiary To Support Growth Of Asia-Pacific Clinical Trials Sector

    Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) solutions for clinical trials, recently announces the opening of a subsidiary in Japan, the world’s third largest pharmaceutical market, where clinical developments have been expanding.

  7. Lupus Foundation Of America Announces Development Of Next Generation Data Platform To Advance Lupus Research

    Recently, the Lupus Foundation of America is excited to announce the development of a next generation data platform supporting the acceleration and advancement of lupus research.

  8. TrialScope Acquires Clinical Trial Connect

    TrialScope, the global leader in transparency and disclosure compliance solutions, has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will join the TrialScope team as Vice President of Patient Engagement.

  9. Global Survey Finds CROs Undergoing Major Changes To Speed Clinical Trials

    Contract research organizations (CROs) are making significant progress in advancing the industrywide move to improve clinical trial performance, according to the Veeva 2019 Unified Clinical Operations Survey: Annual CRO Report, one of the largest-ever surveys of clinical operations professionals globally.

  10. Cesca Therapeutics Forms Joint Venture With HealthBanks Biotech (USA) To Provide Immune Cell Banking And Cell Processing Services

    Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture agreement with HealthBanks Biotech (USA) Inc., one of the world's leading stem cell bank networks, to commercialize its proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO).